However, anti-ActRIIB antibodies failed to show efficacy in a recent sIBM late phase clinical trial (https://www.morphosys.de), suggesting that Mstn signaling is not a prominent driver of muscle atrophy in this disease. Here, MSTN is linked to muscle atrophy.